T1	Participants 218 250	Mediterranean Europe and in Asia
T2	Participants 811 852	patients with pre-core mutant hepatitis B
T3	Participants 936 966	liver disease in most patients
T4	Participants 1039 1124	patients with chronic hepatitis B, including those with pre-core mutant HBV infection
